Methylgene Inc., of Montreal, presented Phase I data for MGCD290, an antifungal compound, showing that all doses and schedules of the drug were tolerated with no severe or serious adverse events, and that pharmacokinetics were dose dependent.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST